Zobrazeno 1 - 10
of 27
pro vyhledávání: '"M. Woler"'
Autor:
Jacques Massol, Alain Puech, Jean-Pierre Boissel, A. Alperovitch, M. Bamberger, B. Bégaud, O. Blin, P. Blin, G. Bréart, C. Brun Strang, M. Buyse, A. Castot, M. Chauvenet, A. Chicoye, N. David, F. De Bels, R. De Sahb Berkovitch, E. Dohin, F. Fagnani, B. Falissard, C. Gastaldi-Menager, I. Giri, M. Haim, J.M. Joubert, M. Lapeyre-Mestre, C. Lassale, I. Marchant Ramirez, F. Meyer, J. Micallef, M. Mollimard, T. Moreau-Defarges, L. Pazart, L. Perret, M. Pigeon, C. Rumeau Pichon, Ph. Tcheng, M. Woler, L. Zanetti, M. Zylberman
Publikováno v:
Therapies. 62:417-425
Resume L’interet de sante publique des medicaments (ISP) est un critere d’evaluation recent (decret d’octobre 1999) et specifiquement francais qui, faute d’elements disponibles au moment de son appreciation, reste a ce jour souvent incomplete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52097f3e2576d994524b4e3f1059511a
https://doi.org/10.2515/therapie:2007072
https://doi.org/10.2515/therapie:2007072
Autor:
Jacques Massol, Alain Puech, Jean-Pierre Boissel, A. Alperovitch, M. Bamberger, B. Begaud, O. Blin, P. Blin, G. Breart, C. Brun Strang, M. Buyse, A. Castot, M. Chauvenet, A. Chicoye, N. David, F. De Bels, R. De Sahb Berkovitch, E. Dohin, F. Fagnani, B. Falissard, C. Gastaldi-Menager, I. Giri, M. Haim, J.M. Joubert, M. Lapeyre-Mestre, C. Lassale, I. Marchant Ramirez, F. Meyer, J. Micallef, M. Mollimard, T. Moreau-Defarges, L. Pazart, L. Perret, M. Pigeon, C. Rumeau Pichon, Ph. Tcheng, M. Woler, L. Zanetti, M. Zylberman
Publikováno v:
Therapie. 62(5)
The Public Health Benefit (PHB) of new medicines is a recent and French-specific criterion (October 1999 decree) which is often only partially documented in the transparency files due to a lack of timely information. At the time of the first reimburs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ea6955521c2706cae53871fb8586e0
https://pubmed.ncbi.nlm.nih.gov/18206104
https://pubmed.ncbi.nlm.nih.gov/18206104
Publikováno v:
Contributions to nephrology. 88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3b1f672d5e613c760896242098225d26
https://pubmed.ncbi.nlm.nih.gov/2040189
https://pubmed.ncbi.nlm.nih.gov/2040189
Autor:
M. Woler, H. Vinazzer
Publikováno v:
Thrombosis Research. 40:135-146
The depolymerized heparin fragment PK 10169 was compared with unfractioned mucosal sodium heparin. The inhibition of factors Xa and IXa by heparin and by PK 10169 was comparable on a weight base, whilst the inhibition of thrombin by PK 10169 was at l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93424a7d3643e9a510bf3b31bb4fb055
https://doi.org/10.1016/0049-3848(85)90324-x
https://doi.org/10.1016/0049-3848(85)90324-x
Publikováno v:
Thrombosis Research. 31:611-621
We present here the in vitro and in vivo evaluation of a new heparin low molecular weight (LMW) derivative that can be prepared on an industrial scale. The in vitro anti activated factor Xa (anti Xa) activity was 67 per cent that of standard heparin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a810dc36e6afc40f11de2c3067a03e7
https://doi.org/10.1016/0049-3848(83)90458-9
https://doi.org/10.1016/0049-3848(83)90458-9
Publikováno v:
Journal of clinical pharmacology. 28(7)
The pharmacokinetics of enoxaparine, a low molecular weight heparin, was randomly studied in 12 healthy male volunteers. Doses of 20, 40, 60, and 80 mg were injected subcutaneously in randomized cross-over fashion. Anti-IIa and anti-Xa activities (us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01c414bd5da0eb431d91545f445d5ae
https://pubmed.ncbi.nlm.nih.gov/2851016
https://pubmed.ncbi.nlm.nih.gov/2851016
Publikováno v:
XIth International Congress on Thrombosis and Haemostasis.
The pharmacokinetics of enoxaparin (E) was randomly studied in 12 healthy male volunteers. Each dose (20-40-60 and 80 mg) was injected via subcutaneous (sc) route with a one-week wash out period. Anti-Xa and anti-IIa activities (ACT), calcium thrombi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daafcdf306acb8a2c8d47d49fbeb6e67
https://doi.org/10.1055/s-0038-1643216
https://doi.org/10.1055/s-0038-1643216
Publikováno v:
Haemostasis. 16(2)
Two hundred and seventy patients over 65 years were included in a placebo-controlled randomized double-blind trial to determine whether a small dose of a low molecular weight (LMW) heparin prevents the occurrence of deep vein leg thrombosis (DVT) dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ef6290519773ae44c5a4d4d8b3c240
https://pubmed.ncbi.nlm.nih.gov/3710294
https://pubmed.ncbi.nlm.nih.gov/3710294
Publikováno v:
Journal des maladies vasculaires. 12
After evaluation of efficacy of a low molecular weight heparin (LMWH), enoxaparine (Lovenox), in patients on continuous hemodialysis without a particular known hemorrhagic risk, this same LMWH was administered during 493 dialysis sessions to 46 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b39feb2f6f930b07aaa66f1f6befdaef
https://pubmed.ncbi.nlm.nih.gov/2834479
https://pubmed.ncbi.nlm.nih.gov/2834479
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.